APA (7th ed.) Citation

H, H., S, S., C, L., & AX, Q. (2025). Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development. Therapeutic innovation & regulatory science, 59(3), 519. https://doi.org/10.1007/s43441-025-00763-5

Chicago Style (17th ed.) Citation

H, Hatcher, Stankeviciute S, Learn C, and Qu AX. "Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development." Therapeutic Innovation & Regulatory Science 59, no. 3 (2025): 519. https://doi.org/10.1007/s43441-025-00763-5.

MLA (9th ed.) Citation

H, Hatcher, et al. "Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development." Therapeutic Innovation & Regulatory Science, vol. 59, no. 3, 2025, p. 519, https://doi.org/10.1007/s43441-025-00763-5.